Co-Chairman and Managing Director
Dr. Reddy's Laboratories Ltd.
G V Prasad leads the core team at Dr. Reddy’s that has contributed significantly to its transformation from a mid-sized domestic operation into a worldwide pharmaceutical conglomerate. Since his fulltime role as CEO in 1990 till date he has seen revenues grow from $50 million to $2.5 billion. He has led the global expansion of the company, especially into developed markets, through both organic and inorganic moves.
Prasad’s emphasis on research, innovation, transparency, business ethics and flatter corporate structures has helped shape Dr. Reddy’s into what it is today - an organization of global repute, recognized industry-wide for scientific innovation, progressive people practices and high standards of corporate governance. He is driving the necessary imperatives for Dr. Reddy’s to engage even more deeply with the human aspects of health.
Prasad is a firm believer in sustainable manufacturing and business practices and leads the company’s sustainability initiatives including the adoption of green technologies and processes. Today, environmental goals are built into operational approaches, thereby reducing the company’s ecological footprint.
As a lover of nature and wildlife, Prasad is involved with the activities of the World Wildlife Fund, AP and Telangana chapter, Wild Life Trust (WTI) of India and other conservation minded organizations.
Bachelors in Chemical Engineering from Illinois Institute of Technology, Chicago, 1982 Masters in Industrial Administration from Purdue University, 1983
Professional Affiliations & Board Memberships
Along with his responsibilities as Co-Chairman and MD, Prasad finds the time and energy to work on other causes that he holds dear. Prasad is a Board Member of institutions such as Indian School of Business and Ashoka University. He has also previously served on the Boards of IIT Hyderabad, S V University, Cyient and Acumen Fund to name a few. He is currently the Chairman of CII National Committee on Pharmaceuticals (2019-20) and has also previously been the Chairman of the CII National Committee on Environment and the Intellectual Property Committee (2006–2007). Prasad has recently been appointed as the Honorary Consul of the Kingdom of Belgium in Hyderabad.
Awards & Recognitions
Boundary Breaker leader Award, CEO Awards 2018
Listed among the Top 50 CEOs that India ever had, Outlook magazine, 2017
One of the top 5 most valuable CEOs of India by Business World, 2016
India Business Leader of the year by CNBC Asia, 2015
India’s Best CEO by Business Today, 2014
India Business Leader of the Year by CNBC Asia, 2014
India Talent Management Award by CNBC Asia, 2014
Mr Vivek V Kamath
Vice Chairman, CII National Committee on Pharmaceuticals & MD & GM EPD - Abbott Specialty Care
Abbott Healthcare Pvt. Ltd.
Vivek V. Kamath
Vice Chairman, CII National Committee on Pharmaceuticals & MD & GM EPD - Abbott Specialty Care Abbott Healthcare Pvt. Ltd.
Vivek V. Kamath was appointed as Managing Director - MSD in India in December 2016.
Vivek has over 25 years of experience in Marketing, Sales and General Management in India, ASEAN & South Asia with healthcare organizations such as Fulford, Warner Lambert, Pfizer, Ranbaxy, Novartis and Roche.
His tenure with MSD in India began in the year 2012 where he was appointed as the Business Unit Director for the Cardiovascular & Metabolic Business. In 2015 he was given the additional responsibility for Market Access & Public Markets Business.
Vivek has led business teams and managed portfolios in prescription, over-the-counter (OTC) & diagnostics segments, partnering with healthcare professionals, consumers, diverse trade channels & government / non-government healthcare entities. He has successfully built megabrands via marketing and sales excellence and also lead integration & cultural change during mergers whilst maintaining business performance.
Vivek Kamath holds a Masters in Marketing Management and Bachelor's degree in Microbiology from the University of Mumbai, India. He has successfully completed MSD’s ‘Emerging Markets Future Leadership program’ (EMFL) and ‘Executive Leadership program’ from Harvard Business School.
CII National Committee on Biotechnology 2019-20
Dr Rajesh Jain
Chairman, CII National Committee on Biotechnology & Managing Director
Panacea Biotec Ltd.
Dr Rajesh Jain
Panacea Biotec Ltd
Dr Rajesh Jain is Managing Director of Panacea Biotec, a leading Biotechnology Company employing over 2,500 people and Chairman, Confederation of Indian Industry (CII), National Committee on Biotechnology for 2019-20. Past Chairman for 2011-12, 2012-13,2018-19. He is recipient of India Innovation Award in 2016 and 2015 (Top 50) by Clarivate Analytics (Formerly Thomson Reuters). Dr Jain is also member of Indian Pharmacopeia (IP) Expert Working on Vaccines and Immunosera for Human Use of in the year 2017. He is also Vice President – Indian Pharmaceutical Alliance (IPA) for 2017-19. He is also Member of Academic Council of DPSRU for three years w.e.f. September 2018. Under his supervision 31 patents has been granted and 33 are under prosecution. Dr. Rajesh Jain’s commitment and actions towards making affordable vaccines for mass population across the globe were appreciated and valued by GAVI and Bill & Melinda Gates Foundation during the pledge conference in June 2011 & in January,2015. Dr Jain led the CII Task Force on Vaccines and organized “National Conference on Vaccine Industry in India” on 10th November 2016. Dr Jian has released two Position papers on a) CII recommendations for Guideline Changes in Vaccine Approval Procedures b)
The Make in India Imperative – Position Paper on Regulatory and Policy Changes required for Sustained competitiveness of the Indian Vaccine Industry. Dr. Rajesh Jain is amongst Top 40 Global most influential persons as per the list put together by World Pharmaceutical Frontiers published in SPG Media, London.
Dr Suresh Jadhav
Co Chairman, CII National Committee on Biotechnology & Executive Director
Serum Institute of India Limited
Dr Suresh Jadhav
Serum Institute of India Limited
Dr.Suresh Jadhav, M.Pharm., Ph.D. is the Executive Director of Serum Institute of India Pvt. Ltd. His 46 years technical expertise includes QC/QA/cGMP/GLP/GCP techniques, inspections of laboratories and validation of various production and quality control processes, pharma/toxicological screening of various drugs, toxins & venoms etc. & drugs pricing. He successfully led the project of development and introduction of Meningococcal A Conjugate Vaccine in Sub-Saharan African belt, the development of Seasonal & Pandemic Influenza Vaccines and also played major role in acquisition of Bilthoven Biologicals, The Netherlands. Being associated with DCVMN since its inception, Dr.Jadhav was its President for 5 years. He held the positions of GAVI Board / Alternate member as also member of GAVI PPC. He is also member on European Vaccine Initiative, FastVac, and Health Innovation in Practice Board etc. He is closely associated with various advisory committees e.g. Task Force of Sabin Vaccine Institute, WHO IVR-IVAC and Decades of Vaccines (DoV) etc. Dr.Jadhav is also affiliated with several Indian universities, AICTE, UGC, State Directorate of Technical Education etc. He is the Chairman of Expert Committee on Vaccines and other Biologicals and also a member on the Scientific Body of Indian Pharmacopoeia Commission. He has participated in several collaborative studies for making revisions in international reference standards for WHO, NIBSC, NVI/RIVM etc. and has published more than 100 technical papers in national & international journals, with extensive travel throughout the globe. He has to his credit two patents in his name. Ranked at 7th position amongst World’s 50 most influential people in Vaccines surveyed by Vaccinenation of Terrapinn. He is conferred with IPA Pune Lifetime Achievement Award 2015 by Indian Pharmaceutical Association.